



**OTHER NEWS TO NOTE.**

BIEWORLD Today  
9 November 2007

**ARCA Discovery** Inc., of Denver, said investigators presented several new analyses of the beta-blocker and vasodilator bucindolol at the American Heart Association Scientific Sessions 2007. An analysis from the 2,708- patient Phase III BEST heart failure trial showed the drug caused a significant reduction in cardiovascular hospitalizations, and a subgroup analysis showed that genetic targeting of the beta-1 AR 389 polymorphism may improve clinical responses to the drug. Additional data showed a positive effect of bucindolol in atrial fibrillation and ventricular arrhythmias. ARCA plans to file a new drug application for the drug and a companion diagnostic.